“Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab”, J of Skin, vol. 9, no. 6, p. s599, Nov. 2025, doi: 10.25251/y4a30r91.